Oscar Health Reports Tomorrow With Analysts Expecting First Sustained Profitability Streak

Oscar Health Inc. (OSCR) is set to report Q2 2026 earnings on August 6, 2026, before market open, with analysts expecting a dramatic turnaround from last year's loss to profitability. The health insurance technology company faces a critical test of whether its recent operational improvements can sustain momentum amid a rapidly evolving healthcare landscape. With the stock trading at $30.11 and Wall Street divided on its valuation, this report will either validate the company's transformation story or raise questions about the sustainability of its recent earnings surprises.

Part 1: Earnings Preview

Oscar Health operates as a technology-focused health insurance company, offering individual and small group plans primarily through the Affordable Care Act exchanges and Medicare Advantage. The company differentiates itself through its proprietary technology platform designed to improve member experience and care coordination.

Oscar Health is scheduled to report Q2 2026 earnings on August 6, 2026, before market open. Analysts expect EPS of $0.65 on revenue of approximately $4.71-4.76 billion. The most recently reported quarter (Q1 2026) delivered actual EPS of $2.07, representing a massive beat that exceeded estimates by 71%.

Compared to the same quarter last year, when Oscar Health reported a loss of $0.89 per share, the current consensus of $0.65 represents a dramatic +173% year-over-year improvement, signaling the company's transition from losses to sustained profitability.

Key themes defining this earnings story:

Medicare Advantage Growth Trajectory: Investors are closely watching Oscar's Medicare Advantage enrollment numbers and per-member profitability metrics. The company has been aggressively expanding in this higher-margin segment, and any acceleration in membership growth or improvement in medical loss ratios would validate the strategic pivot. Analysts note that Medicare Advantage represents the company's most significant growth opportunity, with the potential to drive both top-line expansion and margin improvement.

Technology Platform Monetization: Oscar's proprietary care management technology has been a key differentiator, and the market is looking for evidence that these investments are translating into tangible cost savings and improved member retention. Recent commentary suggests the platform's predictive analytics capabilities are beginning to reduce unnecessary medical spending, which could drive significant operating leverage as the member base scales.

Seasonal Loss Pattern Management: Historically, Oscar has experienced significant losses in Q3 and Q4 due to seasonal healthcare utilization patterns. With Q2 typically representing a profitable quarter, investors will scrutinize management's guidance for the back half of 2026 to assess whether the company can moderate these seasonal swings through improved risk management and care coordination.

Ahead of the release, analysts remain cautiously optimistic but divided. Several firms have raised price targets following the Q1 blowout, citing improved underwriting discipline and operational efficiency. However, some analysts express concern about the sustainability of recent profitability given the company's history of volatile quarterly results and the competitive intensity in both ACA and Medicare Advantage markets.

Part 2: Historical Earnings Performance

Oscar Health has demonstrated a pattern of significant earnings volatility with a recent shift toward positive surprises. Over the past four quarters, the company has beaten or met estimates in three out of four reports, though the magnitude of surprises has varied dramatically.

The most striking result came in Q1 2026, when Oscar reported EPS of $2.07 against an estimate of $1.21, delivering a +71.07% surprise—the largest beat in the company's recent history. This followed a disappointing Q4 2025 result, where the company posted a loss of $1.24 versus an expected loss of $0.84, representing a -47.62% miss that raised concerns about seasonal cost management. The two quarters prior (Q2 and Q3 2025) showed modest beats of +1.11% and +3.64% respectively, suggesting the company had been meeting lowered expectations before the Q1 2026 breakout.

The pattern reveals Oscar's characteristic seasonal earnings profile: the company tends to be profitable or near breakeven in Q1 and Q2, then experiences significant losses in Q3 and Q4 when healthcare utilization typically spikes. The key question for investors is whether the operational improvements that drove the Q1 2026 surprise can help moderate the traditional back-half losses, or if the company will revert to its historical pattern of steep seasonal declines.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Oscar Health reports before market open, meaning Day 0 captures the market's immediate reaction during the first trading session after results are released, while Day +1 reflects follow-through momentum.

Oscar Health has exhibited substantial post-earnings volatility, with an average absolute Day 0 move of 9.15% and Day +1 move of 4.77%. The stock's reaction pattern shows considerable variability, ranging from a dramatic 30.22% surge following the May 2025 report to a 12.28% decline after November 2024 earnings.

The most recent earnings release (May 2026) produced a 10.59% Day 0 gain followed by a 5.19% Day +1 advance, demonstrating sustained positive momentum when results significantly exceed expectations. However, the stock has also shown a tendency for sharp reversals, as seen in November 2024 when a 12.28% Day 0 decline was followed by relative stability. The average Day 0 range of 12.07% indicates investors should prepare for significant intraday volatility regardless of the initial direction, with the Day +1 range of 9.55% suggesting continued movement as the market digests the results and guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 10.22% for this earnings release, which aligns closely with Oscar Health's average historical Day 0 move of 9.15% and sits within the typical range of post-earnings volatility. This suggests options traders are anticipating a reaction consistent with recent patterns, though the stock's history shows potential for moves well beyond this range in either direction.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Oscar Health, with a consensus rating of 3.50 (between Hold and Buy) and an average price target of $25.20. The current rating distribution shows 3 Strong Buys, 1 Moderate Buy, 7 Holds, 1 Moderate Sell, and 0 Strong Sells among the 12 analysts covering the stock.

Sentiment has improved over the past month, with the number of Strong Buy ratings increasing from 2 to 3, while Hold ratings declined from 8 to 7. This shift reflects growing confidence following the company's Q1 2026 earnings blowout and improved operational metrics. The average recommendation has moved from 3.33 to 3.50, indicating a modest but meaningful upgrade in analyst conviction.

The consensus price target of $25.20 implies 16.3% downside from the current price of $30.11, suggesting analysts believe the stock has run ahead of fundamentals despite the improved earnings trajectory. However, the wide range of price targets—from a low of $13.00 to a high of $36.00—reflects significant disagreement about the company's valuation, with bulls seeing potential for further upside if profitability proves sustainable and bears concerned about seasonal losses and competitive pressures eroding recent gains.

Part 4: Technical Picture

Oscar Health enters earnings with a Buy signal at 80% on the Barchart Technical Opinion, though this represents a notable decline from 96% last week and 100% last month, indicating some recent technical deterioration despite the overall bullish posture.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled considerably from recent highs, reflecting consolidation ahead of the earnings event
• Medium-term (100% Buy): Strong buy signal indicates solid intermediate-term trend support remains intact despite short-term softness
• Long-term (100% Buy): Strong buy signal confirms the stock maintains a robust longer-term uptrend, supported by its substantial gains over the past year

Trend Characteristics: The Strong trend with a Weakening direction suggests Oscar Health remains in a well-established uptrend but is experiencing near-term momentum loss as the stock consolidates recent gains heading into the earnings release.

The stock is currently trading at $30.11, positioned above its 10-day ($30.11), 50-day ($28.41), 100-day ($22.57), and 200-day ($19.07) moving averages, but below its 5-day ($30.74) and 20-day ($30.20) moving averages. This configuration shows strong intermediate and long-term trend support, with the stock having gained over 57% from its 200-day average, but recent short-term weakness suggests some profit-taking or caution ahead of the report.

The technical setup presents a mixed picture: while the stock maintains strong support from longer-term moving averages and a solid uptrend, the recent pullback below short-term averages and declining Barchart Opinion readings suggest traders are taking a cautious stance ahead of earnings. The 50-day moving average at $28.41 represents the first significant support level, while the stock's position well above its 100-day and 200-day averages provides a substantial cushion. Given the stock's tendency for large post-earnings moves and the current consolidation pattern, the technical setup is neither strongly supportive nor cautionary—rather, it reflects a market in wait-and-see mode, with the earnings results likely to determine whether the stock breaks out to new highs or pulls back to test stronger support levels.